You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel Insulators in Silicon-on-Insulator Substrates to Improve Nuclear Physics Sensors and Circuits

    SBC: CAPORUS TECHNOLOGIES INC            Topic: C5333c

    C53-33c-271423Active pixel sensors have been developed and implemented in a wide array of applications, including image sensors for cameras, sensors for medical imaging, and as detectors for nuclear physics investigations with the Relativistic Heavy Ion Collider and the Large Hadron Collider. Many of these applications, including nuclear physics detectors, medical imaging sensors, and sensors for ...

    SBIR Phase II 2023 Department of Energy
  2. SBIR Phase I:Creation of antimicrobial MyoMatrix for functional muscle regeneration in a porcine model of volumetric muscle loss

    SBC: GENASSIST INC            Topic: BM

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop an antimicrobial muscle-regenerating biomaterial into a commercial-ready product and address volumetric muscle loss injuries. In the context of defense medicine, severe muscle trauma often occurs in environments where external factors such as sterility are not well-controlled. Th ...

    SBIR Phase I 2023 National Science Foundation
  3. SBIR Phase I:Directed evolution of site-specific bacterial transposase genes to alter specificity and efficiency of insertion of large DNA segments into restorable gene fusions

    SBC: SYNTHETIC VECTOR DESIGNS, LLC            Topic: BT

    The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be to develop methods to facilitate the efficient, reproducible insertion of large DNA segments into stable locations on bacterial vectors, viral and non-viral shuttle vectors, and the chromosomes of prokaryotic and eukaryotic host cells comprising novel target sequences plus helper and donor vectors that cou ...

    SBIR Phase I 2023 National Science Foundation
  4. SBIR Phase II: Building Mathematical Thinking and Problem-solving Skills Together Through Play

    SBC: MATHBRIX LLC            Topic: LC

    This SBIR Phase I project will develop a machine learning-assisted family math preparation program that will help and encourage parents to provide early math instruction to young children, ages 4-8. Along with reading, developing mathematical proficiency is arguably one of the most important skills for young children to acquire, particularly with the growing importance of STEM (science, technology ...

    SBIR Phase II 2023 National Science Foundation
  5. Computer Vision Under Strict Security Constraints: Applications for Robotics

    SBC: MONA MARIE CORPORATION            Topic: X224OCSO1

    Proposed is robotic lawn mower developed and commercialized by the proposing company – Hire Henry. The focus of this Phase I proposal is to quantify the potential impact for fully autonomous, fully electric robotic lawn mowing on United States Air Force Bases. This proposal lays the ground work for future work, which focuses on developing computer vision models for robotic mowing specifically f ...

    SBIR Phase I 2023 Department of DefenseAir Force
  6. SBIR Phase I:Non-invasive Closed Loop Neuromodulation to Treat Obstructive Sleep Apnea

    SBC: NEUROSOMNICSLLC            Topic: MD

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a non-invasive, externally worn appliance for treating obstructive sleep apnea (OSA), a condition affecting over 88 million Americans (26% of the American adult population).Those impacted by OSA are at risk of serious comorbidities such as diabetes, stroke, and heart disease. Many sufferers ...

    SBIR Phase I 2023 National Science Foundation
  7. Increasing Biomass Of TKS/Kazhak Rubber Dandelion To Increase Yields And Reduce Cost Of TKS Rubber

    SBC: KULTEVAT, Inc            Topic: 82

    Kultevat Inc. aims to produce natural rubber from Taraxacum kok-saghyz (TKS) at scale toachieve high quality product at a price point that is attractive to customers in particular to US basedcompanies. To date the economics of growing TKS and extracting rubber from its roots at a pricepoint that is competitive with Hevea rubber has not been demonstrated. During Phase I research anRNAi gene silenci ...

    SBIR Phase II 2023 Department of Agriculture
  8. IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.

    SBC: Shift Pharmaceuticals Holdings, Inc.            Topic: 106

    Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.

    SBC: Antiger Therapeutics Inc.            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government